Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer

K Krishnan K. Mahadevan A Ana S. Maldonado B Bingrui Li A Aaron A. Bickert A Adrian Kacperczyk-Perdyan S Shreyasee V. Kumbhar S Sujan Piya A Amari M. Sockwell S Sami J. Morse K Kent Arian H Hikaru Sugimoto S Shabnam Shalapour D David S. Hong (M.D. Anderson Cancer Center, Houston) T Timothy P. Heffernan A Anirban Maitra R Raghu Kalluri

Article Details

Volume / Issue Vol. 1, Issue 1
Published July 27, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (16)

K

Krishnan K. Mahadevan

A

Ana S. Maldonado

B

Bingrui Li

A

Aaron A. Bickert

A

Adrian Kacperczyk-Perdyan

S

Shreyasee V. Kumbhar

S

Sujan Piya

A

Amari M. Sockwell

S

Sami J. Morse

K

Kent Arian

H

Hikaru Sugimoto

S

Shabnam Shalapour

D

David S. Hong

M.D. Anderson Cancer Center, Houston

T

Timothy P. Heffernan

A

Anirban Maitra

R

Raghu Kalluri